SCHEMBL16361067

SCHEMBL16361067

O=S(=O)(O)c1cnc2c(ccc3cccnc32)c1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 3/20 0.63
▸ TDP1 Q9NUW8 3/20 0.63
▸ MAPT P10636 3/20 0.63
▸ ALDH1A1 P00352 3/20 0.63
▸ LMNA P02545 2/20 0.63
▸ HTT P42858 2/20 0.63
▸ SMN1; SMN2 Q16637 2/20 0.63
▸ L3MBTL1 Q9Y468 2/20 0.63
▸ CCR1 P32246 2/20 0.54
▸ CCR5 P51681 2/20 0.54
▸ CCR8 P51685 2/20 0.54
▸ MMP2 P08253 3/20 0.52
▸ ALOX15 P16050 2/20 0.52
▸ HSP90AA1 P07900 2/20 0.52
▸ TSHR P16473 2/20 0.52
▸ GMNN O75496 1/20 0.52
▸ TP53 P04637 1/20 0.52
▸ CYP3A4 P08684 1/20 0.52
▸ CYP2D6 P10635 1/20 0.52
▸ MMP9 P14780 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16361005 0.88 KDM4E (0.47) KDM4ETDP1MAPTALDH1A1LMNA
SCHEMBL27486389 0.82 LMNA (0.54) KDM4ETDP1MAPTALDH1A1LMNA
Phenanthroline SCHEMBL29101071 0.81 SMN1; SMN2 (0.73) KDM4ETDP1MAPTALDH1A1LMNA
Phenanthroline SCHEMBL1893812 0.80 KDM4E (0.73) KDM4ETDP1MAPTALDH1A1LMNA
Phenanthroline SCHEMBL7486962 0.80 KDM4E (0.73) KDM4ETDP1MAPTALDH1A1LMNA
Phenanthroline SCHEMBL31562164 0.80 KDM4E (0.73) KDM4ETDP1MAPTALDH1A1LMNA
SCHEMBL27346002 0.79 KDM4E (0.53) KDM4ETDP1MAPTALDH1A1LMNA
SCHEMBL17773847 0.79 CCR1 (0.63) KDM4ETDP1MAPTALDH1A1LMNA
Phenanthroline SCHEMBL21750769 0.79 KDM4E (0.70) KDM4ETDP1MAPTALDH1A1LMNA
Phenanthroline SCHEMBL6045194 0.79 KDM4E (0.70) KDM4ETDP1MAPTALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024137765-A1 TRANSITION-METAL CATALYST COMPOSITIONS AND METHODS FOR SEQUENCING BY SYNTHESIS ILLUMINA, INC. (US) 2024-06-27 — — WO disclosed
US-10203333-B2 Electronically neutral metal complexes as biological labels RUBIPY SCIENTIFIC, INC. (CA) 2019-02-12 — — US disclosed
US-20160146826-A1 Electronically Neutral Metal Complexes As Biological Labels HUNAN SANSURE ACCUCISE BIOTECHNOLOGY CO., LTD. (CN) 2016-05-26 — — US disclosed
WO-2014203067-A1 ELECTRONICALLY NEUTRAL METAL COMPLEXES AS BIOLOGICAL LABELS RUBIPY SCIENTIFIC, INC. (CA) 2014-12-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10203333-B2 Electronically neutral metal complexes as biological labels MB, MCU, LETM1 KDM4E 2185/4885TDP1 3505/4885MAPT 3528/4885
US-20160146826-A1 Electronically Neutral Metal Complexes As Biological Labels MB, MCU, LETM1 KDM4E 2185/4885TDP1 3505/4885MAPT 3528/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback